Bioventix Announcements

Bioventix plc (“Bioventix” or “the Company”) Director Dealing   Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal [...]

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual [...]

Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for [...]

Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2022 Highlights: Revenue up 7% to £11.72 million (2021: £10.93 million) Profit before tax up 14% to £9.28 million [...]

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is pleased to announce a [...]

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc   (“Bioventix” or “the Company”)   Director Dealing   Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity [...]

Bioventix plc (“Bioventix” or the “Company”)   Dividend timetable   Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial [...]

Interim results can be downloaded here and are as stated below.   Bioventix plc (“Bioventix” or the “Company”)   Unaudited Interim Results for the six months ended 31 December 2021 [...]